首页> 外文会议>American Peptide Symposium >Effects of Methyl and Halogens in Analgesic Peptide Molecules for Their Potent Agonist Activities at MOR/DOR and Antagonist Activity at NK1R
【24h】

Effects of Methyl and Halogens in Analgesic Peptide Molecules for Their Potent Agonist Activities at MOR/DOR and Antagonist Activity at NK1R

机译:镇痛肽分子在镇痛肽分子中甲基和卤素的影响Mor / Dor和NK1R拮抗剂活性的活性激动剂活性

获取原文

摘要

Treating pain has been always challenging, especially when it becomes chronic in nature. Current drugs (e.g. opioid drugs) cannot treat this problem effectively. In addition, constant use of these drugs has deadly side effects including drowsiness and mental clouding, nausea and emesis, and constipation [1]. Development of analgesic tolerance and hyperalgesia in many patients as the results of taking these drugs are also a serious concern. Overexpression of substance P and its receptor has been observed during prolonged pain states. Studies revealed that co-administration of cocktails of drugs containing μ/δ opioid agonist and NK1 antagonist can provide better analgesic effects in rat model while reducing side effects [2-4]. Herein, we report design, synthesis and SARs of few multifunctional ligands having μ/δ opioid agonist (μ-preferring) and NK1 antagonist activities. The detail of this study has already been communicated to J. Med. Chem. for publication [5]. We anticipate that these ligands will show better analgesia while reducing the adverse side effects. Our drug design principle is based on overlapping and adjacent pharmacophores (Figure 1) and we considered our previously published μ-selective (binding) ligand TY012 (H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bn(3',5'-(CF3)2)) [6].
机译:治疗痛苦一直在具有挑战性,特别是当它变得慢性自然时。目前的药物(例如阿片类药物)不能有效地治疗这个问题。此外,持续使用这些药物具有致命的副作用,包括嗜睡和精神覆盖,恶心和呕吐和便秘[1]。在许多患者中镇痛耐受性和痛觉过敏的发展,因为服用这些药物的结果也是一个严重的问题。在长期疼痛状态期间观察到物质P及其受体的过表达。研究表明,含有μ/δOpiOd激动剂和NK1拮抗剂的药物的共同施用可以在大鼠模型中提供更好的镇痛作用,同时降低副作用[2-4]。在此,我们报告具有μ/δOpiOd激动剂(μ-oldionring)和NK1拮抗剂活性的少数多官能配体的设计,合成和SARS。该研究的细节已经传达给J.Med。化学。出版[5]。我们预期这些配体将显示更好的镇痛,同时降低不良副作用。我们的药物设计原理基于重叠和相邻的药物(图1),我们认为我们以前发表的μ选择性(结合)配体Ty012(H-Tyr-D-Ala-Gly-Phe-Leu-Trp-NH- BN(3',5' - (CF3)2)[6]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号